Adaptive Biotechnologies Corporation $ADPT Shares Purchased by Aberdeen Group plc

Aberdeen Group plc boosted its holdings in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 5.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,046,510 shares of the company’s stock after purchasing an additional 52,543 shares during the quarter. Aberdeen Group plc owned approximately 0.69% of Adaptive Biotechnologies worth $16,995,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in ADPT. Ameriprise Financial Inc. increased its stake in Adaptive Biotechnologies by 84.3% in the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after purchasing an additional 2,731,648 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its stake in Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock worth $36,523,000 after acquiring an additional 2,062,282 shares during the last quarter. Summit Partners Public Asset Management LLC acquired a new stake in Adaptive Biotechnologies during the third quarter worth about $14,934,000. First Trust Advisors LP increased its stake in Adaptive Biotechnologies by 4,802.2% during the second quarter. First Trust Advisors LP now owns 741,306 shares of the company’s stock worth $8,636,000 after acquiring an additional 726,184 shares during the last quarter. Finally, Qube Research & Technologies Ltd increased its stake in Adaptive Biotechnologies by 161.1% during the third quarter. Qube Research & Technologies Ltd now owns 952,229 shares of the company’s stock worth $14,245,000 after acquiring an additional 587,461 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Adaptive Biotechnologies

In other news, insider Susan Bobulsky sold 41,338 shares of the stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $13.17, for a total transaction of $544,421.46. Following the sale, the insider directly owned 427,775 shares in the company, valued at approximately $5,633,796.75. This represents a 8.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Julie Rubinstein sold 19,060 shares of the stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $14.45, for a total value of $275,417.00. Following the sale, the chief operating officer owned 451,540 shares in the company, valued at $6,524,753. The trade was a 4.05% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 2,303,481 shares of company stock worth $33,509,668. 6.40% of the stock is owned by corporate insiders.

Adaptive Biotechnologies Stock Down 4.9%

Shares of NASDAQ ADPT opened at $14.08 on Tuesday. The stock’s 50 day moving average price is $15.35 and its two-hundred day moving average price is $15.98. Adaptive Biotechnologies Corporation has a 52-week low of $6.71 and a 52-week high of $20.76. The stock has a market capitalization of $2.17 billion, a P/E ratio of -35.20 and a beta of 2.29.

Adaptive Biotechnologies (NASDAQ:ADPT) last announced its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The firm had revenue of $71.68 million for the quarter, compared to analysts’ expectations of $59.38 million. During the same quarter in the prior year, the firm posted ($0.23) earnings per share. Adaptive Biotechnologies’s revenue for the quarter was up 51.0% compared to the same quarter last year. On average, analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current year.

Wall Street Analyst Weigh In

ADPT has been the subject of several research analyst reports. Piper Sandler set a $21.00 price target on Adaptive Biotechnologies in a research note on Friday, February 6th. Guggenheim upped their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. TD Cowen reaffirmed a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, JPMorgan Chase & Co. upped their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Adaptive Biotechnologies has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.